Pharmacokinetics of the Tyrosine Kinase Inhibitor, Alectinib

Authors: Al-Ani I*

DOI: 10.23880/beba-16000241

Volume 8, Issue 2

Abstract

In 2015, the FDA authorized the use of a new tyrosine kinase inhibitor, Alectinib (ALB), for the intracellular domain of anaplastic lymphoma kinase with exo-cranial pointed mutations. Alectinib became the first drug to be licensed in the first line in August 2017. Its pharmacological properties differ from those of its predecessors, and new research is needed to identify the potential pharmacological and clinical implications. This review presents a critical analysis of the pharmacokinetics of Alectinib and its impact on hepatobiliary metabolism. We present current clinical data and new knowledge that could be developed for further clinical research. With this study, we hope to identify perspectives that can further prolong the efficacy of the anaplastic lymphoma kinase (ALK) tyrosine kinase Alectinib. Tyrosine kinases with receptors for the ligands of platelet growth are a class of enzymes with a key position in the pathogenesis of various molecular alterations that drive idiopathic cancers. The different characteristics of these kinases make them currently a preferential target for the design of new cancer inhibitors. A clear example of their efficiency is the landmark obtained in patients bearing tumors with intronic rearrangements or ALK translocations. These tumors are mostly found in subjects suffering from non-small-cell lung cancer with adenocarcinoma histology and not of the non-smoking type. Moreover, the development of different resistance mechanisms designated allosteric through targeted second-line interventions has culminated in a marked increase in patient survival.

Keywords: Alectinib; Tyrosine Kinase Inhibitors; Pharmacokinetics

View PDF